Experimental Drug Cuts Abdominal Visceral Fat
A study shows a new injectable treatment can significantly reduce dangerous visceral fat levels in patients.
Updated on Oct. 21, 2026 in Weight Loss
Live Poll
Would you prefer a weight loss treatment that targets fat directly rather than suppressing your appetite?
Researchers presented phase 2 clinical trial results demonstrating that an experimental injectable drug, CBL-514, successfully reduces abdominal visceral fat. The treatment induces natural cell death in fat cells.
Why it matters
Excessive visceral fat is a known precursor to severe health conditions, including insulin resistance, type 2 diabetes, and cardiovascular disease. This treatment offers a targeted approach to reducing this high-risk tissue.
In a 40-participant study, the treatment group achieved a 12.01% reduction in visceral fat at four weeks compared to a 5.68% increase in the placebo group. Follow-up results at 12 weeks showed a 10.45% reduction for treated participants.
The players
CBL-514
This is an experimental drug designed to reduce visceral fat by inducing apoptosis in adipocytes.
EASD
The European Association for the Study of Diabetes is a prominent medical organization that hosts annual conferences to share findings on diabetes research.
The details
The drug CBL-514 is administered via injections into the lower abdomen to trigger apoptosis, the natural process of cell death, within fat cells. Researchers are currently evaluating if the treatment can effectively sustain weight loss for patients transitioning off GLP-1 medications.
Timeline
Four weeks after the final injection, the treatment group showed a 12.01% visceral fat reduction.
Eight to 12 weeks after treatment, the treatment group showed a 10.45% visceral fat reduction.
Health Landscape
This study advances the field of targeted metabolic treatments by exploring fat-cell apoptosis as an alternative to systemic hormone therapy. It represents a shift from current weight-loss benchmarks, such as the development of GLP-1 receptor agonists, by focusing on localized abdominal tissue reduction.
While the results are promising, the drug is not yet available for clinical use as researchers focus on establishing long-term safety profiles. Future trials will determine if this therapy can serve as a practical maintenance tool for those managing weight-related chronic conditions.
The takeaway
Targeted fat reduction remains an area of active investigation to mitigate risks associated with metabolic disease. Patients should continue to consult with healthcare providers regarding established, evidence-based treatments for weight management.
Further reading
For more information on current medical approaches to weight management, visit our Weight Loss section.
Source note: This article includes information reported by Labroots.
Live Poll
Would you prefer a weight loss treatment that targets fat directly rather than suppressing your appetite?
